Progyny (NASDAQ:PGNY) Hits New 52-Week High – Should You Buy?

Progyny, Inc. (NASDAQ:PGNY)’s stock price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $30.33 and last traded at $29.9840, with a volume of 942934 shares traded. The stock had previously closed at $30.22.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Weiss Ratings upgraded Progyny from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, June 26th. Citigroup reissued an “outperform” rating on shares of Progyny in a report on Monday, May 11th. Citizens Jmp upped their target price on shares of Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research report on Monday, May 11th. Wall Street Zen raised shares of Progyny from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Finally, Truist Financial raised their price objective on Progyny from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Eleven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Progyny presently has a consensus rating of “Moderate Buy” and an average target price of $29.92.

Progyny Stock Performance

The firm has a market capitalization of $2.37 billion, a PE ratio of 39.36, a PEG ratio of 2.67 and a beta of 1.01. The company has a fifty day moving average price of $24.58 and a 200-day moving average price of $22.50.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm had revenue of $328.50 million during the quarter, compared to analyst estimates of $326.46 million. During the same period last year, the firm posted $0.17 earnings per share. Progyny’s revenue for the quarter was down 26.4% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, equities analysts predict that Progyny, Inc. will post 1.07 earnings per share for the current year.

Progyny declared that its board has approved a stock buyback plan on Tuesday, May 26th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to reacquire up to 10.3% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In other Progyny news, COO Melissa B. Cummings sold 9,578 shares of Progyny stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $25.00, for a total value of $239,450.00. Following the completion of the transaction, the chief operating officer directly owned 73,371 shares of the company’s stock, valued at $1,834,275. This trade represents a 11.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the sale, the insider owned 59,117 shares in the company, valued at approximately $1,512,212.86. This trade represents a 2.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 36,916 shares of company stock worth $939,875. Insiders own 9.90% of the company’s stock.

Institutional Investors Weigh In On Progyny

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PGNY. Caitong International Asset Management Co. Ltd bought a new position in shares of Progyny during the 4th quarter valued at approximately $25,000. Hantz Financial Services Inc. boosted its stake in Progyny by 79.4% during the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after buying an additional 742 shares during the period. Canada Pension Plan Investment Board bought a new position in Progyny during the second quarter valued at $77,000. Quarry LP raised its stake in shares of Progyny by 2,004.1% in the third quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after acquiring an additional 3,427 shares during the period. Finally, New Age Alpha Advisors LLC purchased a new stake in shares of Progyny in the fourth quarter valued at $94,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.